Dr Reddy's stock: Product pipeline should boost revenue growth in FY19

Analysts at Nomura believe there is a strong probability that the company will get approval in the near term for Suboxone & expect initially lower competitive intensity

The Dr Reddy’s stock gained on Tuesday over 5 per cent in trade, on expectation that the company would be soon launching a generic version of opioid treatment drug Suboxone. Coupled with its other launches in FY19 in the US, this should boost its profit.

Analysts at Nomura believe there is a strong probability that the company will get approval in the near term for Suboxone, and expect initially lower competitive intensity. They estimate an annualised earnings per share impact of Rs 62.5 without additional generic competition. While the indications are positive, any adverse court ruling or launch by other companies